Want to see KRSA full AI Analyst Report?
KRSA Stock Chart & Stats
$4.15
$0.00(0.00%)
At close: 4:00 PM EST
$4.15
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$7.18 - $59.36
Previous CloseN/A
VolumeN/A
Average Volume (3M)124.03K
Market Cap
$1.37B
Enterprise Value$2.28M
Total Cash (Recent Filing)$1.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.78
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,541,360
10 Day Avg. Volume191,129
30 Day Avg. Volume124,035
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.45
Price to Sales (P/S)1.97
P/FCF Ratio-1.24
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue1.20
Enterprise Value/Gross Profit1.95
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$53.00Price Target Upside1177.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Equity PositionA strong equity position with no debt provides financial stability and flexibility, allowing Cyclerion to focus on R&D without the pressure of debt repayments.
High Gross Profit MarginMaintaining a high gross profit margin indicates efficient cost management in revenue-generating years, which is crucial for future profitability as the company scales.
Focus On CNS DisordersTargeting CNS disorders with high unmet needs positions Cyclerion to potentially capture significant market share if their therapies succeed, driving long-term growth.
Bears Say
Persistent Net LossesOngoing net losses highlight operational inefficiencies and the challenge of achieving profitability, which can hinder long-term financial health and investment capacity.
Negative Cash FlowNegative cash flow restricts Cyclerion's ability to invest in R&D and scale operations, potentially limiting future growth and sustainability.
Inconsistent Revenue GrowthInconsistent revenue growth reflects challenges in product development and market penetration, which could affect long-term viability and investor confidence.
Korsana Biosciences News
KRSA FAQ
What was Korsana Biosciences’s price range in the past 12 months?
Korsana Biosciences lowest stock price was $7.18 and its highest was $59.36 in the past 12 months.
What is Korsana Biosciences’s market cap?
Korsana Biosciences’s market cap is $1.37B.
When is Korsana Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Korsana Biosciences’s earnings last quarter?
Currently, no data Available
Is Korsana Biosciences overvalued?
According to Wall Street analysts Korsana Biosciences’s price is currently Undervalued.
Does Korsana Biosciences pay dividends?
Korsana Biosciences does not currently pay dividends.
What is Korsana Biosciences’s EPS estimate?
Korsana Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Korsana Biosciences have?
Korsana Biosciences has 45,541,360 shares outstanding.
What happened to Korsana Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Korsana Biosciences?
Currently, no hedge funds are holding shares in KRSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korsana Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.00 (1177.11% Upside)
$53.00 (1177.11% Upside)
Blogger Sentiment
Bullish
KRSA Sentiment 100%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 51.1K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
124.25%
12-Months-Change
Fundamentals
Return on Equity
-87.96%
Trailing 12-Months
Asset Growth
-26.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Korsana Biosciences
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
KRSA Stock 12 Month Forecast
Average Price Target
$53.00
▲(1177.11% Upside)
Technical Analysis
Ownership Overview
2.29% Insiders
<0.01% Other Institutional Investors
97.69% Public Companies and
Individual Investors